KDR and prostate carcinoma: To date, BR55, a VEGFR2 targeting bubble for cancer detection [54], different in composition and conjugation chemistry to ours (Table A in S1 File), is the only targeting bubble tested in humans (Phase-0-2 clinical trial in prostate cancer) [23, 24]–the results are still awaited.